Evidence map›Paper›PMID 41085848›Full record

ReviewDiscover oncology2025

Recent advances in immunotherapy for breast cancer.

Yi Guo, Gang Zheng, Yu Fan, Liangchang Li, Yang Sun

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yi GuoDepartment of Anatomy, Histology and Embryology, Medical College, Jilin Key Laboratory of Anaphylactic Disease, Yanbian University, Yanji, 133002, P. R. China.
Gang ZhengThird Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130000, P. R. China.
Yu FanThird Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130000, P. R. China.
Liangchang LiDepartment of Anatomy, Histology and Embryology, Medical College, Jilin Key Laboratory of Anaphylactic Disease, Yanbian University, Yanji, 133002, P. R. China. lclee@ybu.edu.cn.
Yang SunThird Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130000, P. R. China. wwwsunyangnet@163.com.

Funding

Jilin Provincial Department of Education Science and Technology Research Project JJKH20241078KJ
6 · The paper itself

Abstract

Cancer immunotherapy is now defined as enhancing the immune function of patients through active or passive methods, such as biological therapy, to achieve the goal of killing tumor cells. With increasing morbidity and mortality rates annually, breast cancer (BC) is the most diagnosed cancer in the world in 2023, surpassing lung cancer, colon cancer and stomach cancer. Immunotherapy plays an important role in treating BC and provides patients with other new options. Numerous studies have recognized the feasibility of immunotherapy in BC, and many innovative treatment methods have been proposed. In this article, we review the advances in and types of treatments for BC, especially the challenges and opportunities in integrating these therapies, a topic that has not been systematically explored in previous studies, with the aim of providing a reference for clinical treatment.

Indexed as

Breast cancerCheckpointImmunotherapyMonoclonal antibodyTargeted drugs

Identifiers

PMID41085848
PMCPMC12521729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.